ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES INCLUSION OF FUTURE MEDICAL COSTS IN HEALTH TECHNOLOGY ASSESSMENT GUIDELINES

Published Nov 2, 2016
Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel entitled, Should Health Technology Assessment Guidelines Recommend Inclusion of Future Medical Costs?, at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Andrew Briggs, DPhil, MSc, William R, Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK. Panelists for the issue panel included:
  • Alec Morton, PhD, Professor, Management Science, University of Strathclyde, Glasgow, UK
  • Pieter van Baal, PhD, Associate Professor, Institute for Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
  • Ad Antonisse, MSc, Director Economic Affairs (Market Access and Public Affairs), AstraZeneca, Zoetermeer, The Netherlands
This session explored whether health technology assessment (HTA) guidelines should recommend the inclusion of “unrelated future costs” of a medical technology. Recently, Dutch HTA guidelines were changed to recommend inclusion of future, unrelated medical costs. Currently, however, many HTA guidelines exclude future medical costs from an appraisal. For example, the costs of caring for a patient with dementia after preventing death from stroke would not be included in a cost effectiveness analysis of a thrombolysis treatment. The panelists presented the benefits and disadvantages of including future, unrelated costs in HTA guidelines. Alec Morton, PhD provided a summary of theoretical arguments for and against inclusion of future unrelated medical costs. Pieter van Baal, PhD reviewed approaches for how these future costs can be estimated in practice. Ad Antonisse, MSc provided the industry perspective on the issue. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

ISPOR Chief Science Officer Dr Laura Pizzi Named to NJBIZ's 2026 People to Watch in Healthcare List

Jul 29, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) is proud to announce its Chief Science Officer, Laura Pizzi, PharmD, MPH, has been recognized by NJBIZ as one of its 2026 People to Watch in Healthcare.

ISPOR Publishes White Paper Focused on Systemic Coherence for Healthcare Decision Making in Europe

Jul 21, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has released a new white paper, “Achieving Systemic Coherence for Healthcare Decision Making in Europe.”

ISPOR Announces the Healthcare Investment Summit 2026

Jul 20, 2026

ISPOR announced their inaugural Healthcare Investment Summit 2026, which will bring together healthcare investors, founders, pharma and device executives, policy experts, health economists, and access leaders on September 22–23, 2026, in San Francisco to examine the critical factors shaping investment decisions across the healthcare landscape.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×